载阿霉素靶向制剂治疗肝癌研究现状  

Research Situation of Nano-drug Doxorubicin Targeting Treatment of Hepatoma

作　　者：戚宁[1,2] 杜明华[1,2] 

机构地区：[1]东南大学临床医学院 [2]江苏省中医院核医学科,南京210009

出　　处：《医学综述》2012年第11期1663-1665,共3页Medical Recapitulate

基　　金：东南大学国家自然科学基金预研项目(9290001412)

摘　　要：药物缺乏选择性是目前肿瘤化疗的主要问题,为提高药物疗效,减少不良反应,人们开始对靶向载药制剂进行探索。靶向药物制剂最突出的优点是靶向性明显,能在靶位保持有效药物浓度和时间。近些年越来越多的靶向制剂用于肝癌的靶向治疗。现对抗肿瘤药物阿霉素靶向制剂治疗肝癌的研究现状进行综述,并指出其治疗前景及存在的若干问题。At present,the main problem of the drugs to the tumors used in clinic is the non-selectivity in vivo.People have started to do more researches on the targeting ultrastructure and the systems of controlling release for improving the drug-efficiencies and decreasing the side-effects.The most prominent advantage of targeting drug is the obvious target orientation and maintaining of effective drug concentration and time at the target postions.More and more targeted agents have been used for hepatocellular carcinoma targeting therapy.Here is to make a review on the situation and advancement of drug-nanoparticles′carrying agents of doxorubicin for treating hepatoma in recent years and the existing problems as well as the prospect.

关 键 词：肝癌 阿霉素 纳米粒 

分 类 号：R453.9[医药卫生—治疗学]